RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Clinical trials for RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Real-world data on epcoritamab for tough-to-treat lymphoma
Disease control OngoingThis study tracks how well the drug epcoritamab works for 150 adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried at least two other treatments. Researchers will measure tumor shrinkage and side effects in everyday medical practice, not…
Matched conditions: RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Andrés José Maria Ferreri • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Could a higher stem cell dose beat back lymphoma?
Disease control OngoingThis study looks at whether giving more stem cells during an autologous transplant helps people with relapsed or refractory diffuse large B-cell lymphoma recover better and stay cancer-free longer. About 59 adults who have already tried one chemotherapy will get high-dose chemo (…
Matched conditions: RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC